- H-89
-
- $34.00 / 5mg
-
2025-05-08
- CAS:127243-85-0
- Min. Order:
- Purity: 98.06%
- Supply Ability: 10g
- H-89
-
- $34.00 / 5mg
-
2025-05-08
- CAS:127243-85-0
- Min. Order:
- Purity: 98.06%
- Supply Ability: 10g
- H-89 dihydrochloride
-
- $1.00 / 1KG
-
2019-12-23
- CAS:127243-85-0
- Min. Order: 1KG
- Purity: 97%-99.9%
- Supply Ability: 100kg
|
| | N-(2-[P-BROMOCINNAMYLAMINO]ETHYL)-5-ISOQUINOLINESULFONAMIDE HYDROCHLORIDE Basic information |
| | N-(2-[P-BROMOCINNAMYLAMINO]ETHYL)-5-ISOQUINOLINESULFONAMIDE HYDROCHLORIDE Chemical Properties |
| Melting point | 195-200°C | | Boiling point | 639.7±65.0 °C(Predicted) | | density | 1.436 | | storage temp. | 2-8°C | | solubility | H2O: ≥10 mg/mL | | pka | 10.43±0.50(Predicted) | | form | powder | | color | off-white | | Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or distilled water may be stored at -20°C for up to 3 months. | | CAS DataBase Reference | 127243-85-0(CAS DataBase Reference) |
| Safety Statements | 22-24/25 | | WGK Germany | 3 | | HS Code | 29350090 |
| | N-(2-[P-BROMOCINNAMYLAMINO]ETHYL)-5-ISOQUINOLINESULFONAMIDE HYDROCHLORIDE Usage And Synthesis |
| Description | H-89 (127243-85-0) is a commonly used inhibitor of protein kinase A (PKA? IC50?= 140 nM).? Inhibits a variety of other kinases including S6K1 (IC50?= 80 nM), MSK1 (120 nM), ROCK II (270 nM), PKBα (2.6 μM), PKD, PRK2, RSK1 and 2, SGK, AMPK, CHK1 and MAPKAP-K1b (2.8 μM).1,2 | | Chemical Properties | White Solid | | Uses | Selective inhibitor of Protein Kinase A (cyclic AMP-dependeant Protein Kinase) with an inhibitory constant of 0.0048 uM. | | Definition | ChEBI: A member of the class of isoquinolines that is the sulfonamide obtained by formal condensation of the sulfo group of isoquinoline-5-sulfonic acid with the primary amino group of N1-[3-(4-bromophenyl)prop-2-en-1-yl]et
ane-1,2-diamine. | | General Description | A cell-permeable, selective, reversible, ATP-competitive and potent inhibitor of protein kinase A (Ki = 48 nM). Inhibits other kinases at several fold higher concentrations: myosin light chain kinase (Ki = 28.3 μM), Ca2+/calmodulin-dependent protein kinase II (Ki = 29.7 μM), protein kinase C (Ki = 31.7 μM), casein kinase I (Ki = 38.3 μM), and Rho Kinase II (IC50 = 270 nM). May be used to discriminate between the effects of PKA and cAMP-regulated guanine-nucleotide-exchange factors (GEFs), such as GEFI or Epac (exchange protein directly activated by cAMP) and GEFII. Reported to induce neurite formation in NG 108-15 cells (~1 mM) by blocking the action of Rho kinase II. | | Biological Activity | Protein kinase A inhibitor that also inhibits several other kinases (IC 50 values are 80, 120, 135, 270, 2600 and 2800 nM for S6K1, MSK1, PKA, ROCKII, PKB α and MAPKAP-K1b). | | Biochem/physiol Actions | Target Ki: 48 nM for protein kinase A | | References | 1) Lochner and Moolman (2006),?The many faces of H89: a review; Cardiovasc. Drugs,?24?261
2) Bain?et al. (2007),?The selectivity of protein kinase inhibitors: a further update; Biochem.J.?408(Pt3)?297 |
| | N-(2-[P-BROMOCINNAMYLAMINO]ETHYL)-5-ISOQUINOLINESULFONAMIDE HYDROCHLORIDE Preparation Products And Raw materials |
|